AzTrials
AzTrials

Coronary Artery DiseaseRIPCORDNCT01070771

Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?

A study testing Radi pressure wire (pressure wire assessment) in people with Coronary Artery Disease, run by University Hospital Southampton NHS Foundation Trust at 10 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The use of coronary angiography to investigate patients at risk of coronary artery narrowings has become universal. In most cases, this investigation leads to a successful treatment plan with revascularisation recommended where appropriate. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Coronary Artery Disease
What is being tested?
Radi pressure wire (pressure wire assessment)
Type of treatment
Medical device
How many people
203 participants
Where
10 sitesin 2 countries
Study dates
Jun 2008to Aug 2012
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients referred for elective coronary angiography under a non-interventional cardiologist for the investigation of chest pain thought to be of cardiac origin.
  • There is no requirement for a test demonstrating objective evidence of myocardial ischaemia because this study aims to recruit consecutive patients in real world current practice
  • Written informed consent
  • No participation in other studies

Who cannot join

  • Previous coronary artery bypass graft surgery
  • Acute coronary syndrome at presentation
  • Diagnostic angiography or percutaneous coronary intervention within the previous 12 months
  • Contraindication to adenosine
  • Severe valve disease
  • Creatinine >180
  • Life threatening comorbidity
  • Diagnostic angiogram showing "normal" coronary arteries defined as no coronary stenosis of >30% by visual estimate in any epicardial vessel of >2.25mm diameter

Trial locations and contacts

10 sites in 2 countries.

10 sites in 2 countries

United Kingdom9 sites
  • Royal Sussex County Hospital

    Brighton, BN2 5BE

  • Dr Kamal Chitkara

    Derby, DE22 3NE

  • West of Scotland Regional Heart & Lung Centre

    Glasgow, G81 4HX

  • Dr Steve Wheatcroft

    Leeds, LS1 3EX

  • Freeman Hospital

    Newcastle upon Tyne, NE7 7DN

  • John Radcliffe Hospital

    Oxford, OX3 9DU

  • Dr Alex Hobson

    Portsmouth, Hampshire, PO6 3LY

  • Southampton General Hospital

    Southampton, SO16 6YD

  • Dr Dan McKenzie

    Taunton, Somerset, TA1 5DA

Other trials in United Kingdom

Ireland1 site
  • Dr Colm Hanratty

    Belfast, BT9 7AB

Other trials in Ireland

About this study

The use of coronary angiography to investigate patients at risk of coronary artery narrowings has become universal. In most cases, this investigation leads to a successful treatment plan with revascularisation recommended where appropriate. However in a substantial number of patients, the images taken of the coronary arteries can lead to diagnostic uncertainty. Increasingly, doctors are using devices called pressure wires to clarify the significance of coronary artery narrowings in order to tailor patient treatment on an individual basis.

The Radi pressure wire is well recognised as a reliable tool in assessing whether a narrowing is significant in functional terms, that is, does it significantly restrict blood flow to the heart muscle.It consists of a fine wire that is fed into individual major coronary arteries to measure pressure within the vessel itself. In conjunction with the images taken of the arteries, it is very useful in deciding how best to treat patients.

This study enrolls volunteers who are being investigated for stable cardiac-sounding chest pain and are undergoing a coronary angiogram. It will investigate whether the extra information gained from pressure wire assessment will change patients' treatment plan.

Read the detailed description

The choice of management in an individual patient is determined largely by the presence and distribution of significant coronary narrowings. Usually, this significance is judged by the visual estimation of a narrowing on an angiogram. However, although this is the standard way of assessing coronary narrowings, it is now widely published that pressure wire measurements are more accurate because they assess the true physiological consequences of the narrowing. Interventional cardiologists now frequently use Fractional Flow Reserve (FFR) measurements to help them decide if arteries require stenting.The hypothesis for this study is that routine measurement of FFR in the main coronary arteries could provide diagnostic information above and beyond that obtained by an angiogram alone. This additional information may well then affect the choice of management in a proportion of these patients. For example, a narrowing considered to be significant angiographically may be shown to be insignificant with FFR, or vice versa.

Background

Coronary artery disease (CAD) is a major cause of morbidity and mortality in the United Kingdom. It accounts for approximately half of all cardiovascular related deaths annually and, according to statistics from the British Heart Foundation, CAD related expenditure was £3,500 million in 2003 alone. Much effort has been placed on improving methods that detect and assess the severity of CAD and facilitate more rapid and appropriate management for CAD patients. Once diagnosed, CAD may be treated in 3 ways: (1)tablets alone, (2)tablets plus angioplasty with stents or (3) tablets plus coronary artery bypass graft surgery (CABG). The method of choice depends primarily on the extent and severity of disease at the time of coronary angiography. Coronary angiography is the current conventional method for the diagnosis of CAD and is used in the assessment of disease severity. For the angiographic procedure,vascular access is secured via the femoral artery or radial artery route and a dye is injected into the coronary artery blood vessels. The progress of the dye through the coronary blood vessels provides a visual assessment of where narrowings are present in the coronary arteries.

Where there is thought to be significant flow obstruction, particularly in symptomatic patients, one of the above three treatments will be offered.

While coronary angiography has revolutionised the management of CAD, the procedure is not without limitation. The purely visual assessment of disease severity with coronary angiography is subjective and patient management can depend on the cardiologist reviewing the films. Many such narrowings can be graded 'moderate' severity and deciding whether these are of haemodynamic significance is notoriously difficult by angiography alone. In recent years, the Radi pressure wire has been shown to provide accurate physiological haemodynamic data about coronary narrowings. Furthermore, the FFR measurement derived predicts clinical outcome, hence giving a 'cut-off' measurement for severity of disease that correlates with the requirement for revascularisation with either stents or surgery. Thus FFR is now frequently used in clinical practice by interventional cardiologists to decide if narrowings require treatment. However, the majority of diagnostic angiography in the UK is performed by non-interventional cardiologists who do not currently have access to the pressure wire technology. In this study, we speculate that if we measure the FFR routinely in all the main coronary arteries of patients undergoing coronary angiography the FFR data obtained may affect the angiogram-derived management of some patients in terms of the choice of tablets/stents/CABG. For example, some narrowings that look significant angiographically may not be haemodynamically important by FFR and vice versa. Clearly this could make a difference between revascularising a patient or not.

Research Aims

To evaluate:

  1. The degree of correlation between standard angiographic assessment of the coronary arteries and pressure wire assessment of the main arteries.
  2. To determine whether the FFR data would influence the management strategy for patients as derived only on the basis of the angiogram (which represents clinical practice).

Methods and Design

The study will recruit 200 patients listed for diagnostic coronary angiography performed by a non-interventional cardiologist.

Methodology 1: In Catheter Laboratory

  • All patients will receive an information sheet after initial invitation to take part.
  • Written informed consent will be obtained.
  • Patients will undergo coronary angiography in a routine manner.
  • The non-interventional cardiologist in charge of the patient's care will analyse the pictures and grade the outcome in the manner shown in table 1. He/she will formulate a management plan consistent with their routine clinical practice and independent of subsequent pressure wire data. This management plan will be documented in the CRF. He/she will then take no further part in the procedure.

Table 1

  1. Are there significant stenoses (>70% by eyeball) in the major epicardial vessels (i.e. main coronaries or any branch of >2.25mm)
  2. Recommend revascularisation or medical/conservative treatment
  3. If revascularisation: recommended strategy for referral (Percutaneous Coronary Intervention (PCI) or CABG?) and which vessels (i.e. LAD + RCA etc) represent targets for that revascularisation
  • The management strategy will be recorded according to the following options:
  1. medical;
  2. PCI
  3. CABG
  • Data will also be collected in regard to vessels as targets (i.e. which vessels require stent/graft)
  • If the non-interventional cardiologist cannot make a plan they can allocate the patient to a fourth category in which "more data are required". Such patients are generally then referred for further non-invasive stress imaging or even for a pressure wire.
  • FFR measurements will then be undertaken by a consultant interventional cardiologist
  • Additional screening time and contrast use accrued during FFR measurements will be recorded.
  • The patient will be given 70units/kg heparin i.a. or i.v. prior to passage of the pressure wire
  • A pressure wire will be introduced into the distal third of all patent major epicardial coronary arteries and branches of >2.25mm with TIMI 3 flow.
  • FFR measurements will be taken using either intracoronary or intravenous adenosine according to local conventional practice and operator preference.
  • The protocol mandates i.v. adenosine for ostial LM stem and ostial RCA stenoses.
  • Where i.c. adenosine bolus is employed, the minimum data required by the study is: 1 baseline FFR without adenosine and 2 boluses with at least 50mcg adenosine.
  • An angiogram will be acquired before the first adenosine measurement to document satisfactory engagement of the guiding catheter and the position of the measurement in each vessel
  • The minimum FFR reading will be taken in each case
  • FFR readings of <0.8 will be considered as representing haemodynamic significance as per FAME protocol
  • Once the FFR data are derived the procedure will be finished and haemostasis will be achieved in the normal manner
  • Provided the angiogram-derived management plan has been recorded in the CRF then the FFR data can then be revealed to the non-interventional cardiologist. The management plan will then be recorded in the light of the FFR data using the same categories and dataset as previously.
  • The non-interventionalists will then manage the patient as they see fit

Analysis

PRIMARY ENDPOINT Estimation of number of cases where FFR data results in a change in the management strategy the revascularisation strategy (number of vessel requiring treatment and/or PCI vs medical vs CABG)

Potential Clinical Value

If this study proves its hypothesis, it will suggest that coronary angiography would be better supported by routine pressure wire assessment in order to tailor revascularisation strategies for individual patients more accurately. The result of this study will carry important clinical implications if the study hypothesis is proven.... not least in terms of potential patient benefit. The current widely held practice of diagnostic test followed by either (i) referral for revascularisation or, (ii) in the case of equivocal angiographic results, referral for stress imaging to look for objective evidence of ischaemia followed by referral for revascularisation where positive could be rendered obsolete by diagnostic angiography performed by interventional cardiologists with FFR availability and the ability to perform PCI at the same sitting where appropriate.

The study may generate the hypothesis that such routine FFR measurement will not only be of benefit to patients but also be cost-effective if there would have been fewer interventions overall (ie less CABG + PCI) or fewer expensive interventions (i.e. less CABG versus PCI)?

Being tested
Radi pressure wire (pressure wire assessment)
Keywords
Pressure wire, Fractional flow reserve
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Radi pressure wire (pressure wire assessment)Device

    Also called Radi pressure wire.

    Intracoronary insertion of pressure wire at the time of diagnostic angiography.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Estimation of Number of Cases Where FFR Data Results in a Change in the Management Strategy (Number of Vessel Requiring Treatment and/or PCI vs Medical vs CABG)

    This outcome measure was assessing agreement in the management plan (MP) derived from angiographic assessment alone compared to a MP derived from angiographic assessment plus the use of FFR data acquired at the time of angiography. The study assessed the proportion of cases in which the angiogram directed MP changed after FFR data were disclosed.

    Measured: Up until hospital discharge. Most cases were day cases but no specific data relating to length of stay collected.

Secondary outcomes (1)
  1. To Determine the Level of Agreement in Management Plans Regarding the Significance of Coronary Artery Narrowings When Comparing the MP Acquired by Standard Angiographic Assessment Alone and a MP Acquired Using Angiographic Assessment Plus FFR Data.

    This compared the number of vessels in which there was a discrepant result in relation to angiographically and FFR defined significance. Angiographic significance was visually assessed by operators whereas the pressure wire provided objective data as to a narrowing's significance: an FFR reading of <0.8 indicated a significant restriction in blood flow with a recommendation for revascularisation.

    The difference in indication for revascularisation of each major coronary artery was also judged according to angiogram alone compared with angiogram plus FFR dtaa.

    Measured: Up to hospital discharge. Most were day case procedures but no specific data relating to discharge was collected.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2010 (estimated)
  2. Study startJun 2008
  3. Primary completionAug 2012
  4. Study completionAug 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
203 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01070771
Sponsor's protocol ID
Version 3 dated 01/10/2009
Other IDs
5327
Acronym
RIPCORD
Status last verified
Oct 2015
First submitted
17 Feb 2010
Last updated
22 May 2019
Data monitoring committee
Yes

Publications

  • Curzen N, Rana O, Nicholas Z, Golledge P, Zaman A, Oldroyd K, Hanratty C, Banning A, Wheatcroft S, Hobson A, Chitkara K, Hildick-Smith D, McKenzie D, Calver A, Dimitrov BD, Corbett S. Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain?: the RIPCORD study. Circ Cardiovasc Interv. 2014 Apr;7(2):248-55. doi: 10.1161/CIRCINTERVENTIONS.113.000978. Epub 2014 Mar 18.

    PubMed 24642999
  • Bashar HAB, Saunders A, Alaour B, Gerontitis D, Hinton J, Karamanou D, Kechagioglou G, Olsen S, Onwordi E, Pope M, Zingale A, Nicholas Z, Golledge P, Escaned J, Ali Z, Curzen N. Systematic coronary physiology improves level of agreement in diagnostic coronary angiography. Open Heart. 2023 May;10(1):e002258. doi: 10.1136/openhrt-2023-002258.

    PubMed 37130658
  • Stables RH, Mullen LJ, Elguindy M, Nicholas Z, Aboul-Enien YH, Kemp I, O'Kane P, Hobson A, Johnson TW, Khan SQ, Wheatcroft SB, Garg S, Zaman AG, Mamas MA, Nolan J, Jadhav S, Berry C, Watkins S, Hildick-Smith D, Gunn J, Conway D, Hoye A, Fazal IA, Hanratty CG, De Bruyne B, Curzen N. Routine Pressure Wire Assessment Versus Conventional Angiography in the Management of Patients With Coronary Artery Disease: The RIPCORD 2 Trial. Circulation. 2022 Aug 30;146(9):687-698. doi: 10.1161/CIRCULATIONAHA.121.057793. Epub 2022 Aug 10.

    PubMed 35946404

Questions about this trial

What is this clinical trial studying?

A study testing Radi pressure wire (pressure wire assessment) in people with Coronary Artery Disease, run by University Hospital Southampton NHS Foundation Trust at 10 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in United Kingdom, Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 11 Nov 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Estimation of Number of Cases Where FFR Data Results in a Change in the Management Strategy (Number of Vessel Requiring Treatment and/or PCI vs Medical vs CABG) (time frame: Up until hospital discharge. Most cases were day cases but no specific data relating to length of stay collected.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01070771, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
RIPCORD Clinical Trial NCT01070771 | AzTrials